The Tech Brunch The Tech Brunch

The Tech Brunch

The Tech Brunch

  • Home
  • Startups
  • Social
  • Enterprise
  • Gadgets
  • Greentech
  • Mobile
  • Fundings and exits
The Tech BrunchThe Tech Brunch
  • Startups
  • Social
  • Enterprise
  • Gadgets
  • Greentech
  • Mobile
  • Fundings and exits
Home > Startups > YC startup Felix wants to replace antibiotics with programmable viruses
Startups

YC startup Felix wants to replace antibiotics with programmable viruses

Published: Apr 13, 2022

Right now the world is at war. But this is no ordinary war. It’s a fight with an organism so small we can only detect it through use of a microscope — and if we don’t stop it, it could kill millions of us in the next several decades. No, I’m not talking about COVID-19, though that organism is the one on everyone’s mind right now. I’m talking about antibiotic-resistant bacteria.

You see, more than 700,000 people died globally from bacterial infections last year — 35,000 of them in the U.S. If we do nothing, that number could grow to 10 million annually by 2050, according to a United Nations report.

The problem? Antibiotic overuse at the doctor’s office or in livestock and farming practices. We used a lot of drugs over time to kill off all the bad bacteria — but it only killed off most, not all, of the bad bacteria. And, as the famous line from Jeff Goldblum in Jurassic Park goes, “life finds a way.”

Enter Felix, a biotech startup in the latest Y Combinator batch that thinks it has a novel approach to keeping bacterial infections at bay – viruses.

\"\"

Phage killing bacteria in a petri dish

It seems weird in a time of widespread concern over the corona virus to be looking at any virus in a good light but as co-founder Robert McBride explains it, Felix’s key technology allows him to target his virus to specific sites on bacteria. This not only kills off the bad bacteria but can also halt its ability to evolve and once more become resistant.

But the idea to use a virus to kill off bacteria is not necessarily new. Bacteriophages, or viruses that can “infect” bacteria, were first discovered by an English researcher in 1915 and commercialized phage therapy began in the U.S. in the 1940’s through Eli Lilly and Company. Right about then antibiotics came along and Western scientists just never seemed to explore the therapy further.

However, with too few new solutions being offered and the standard drug model not working effectively to combat the situation, McBride believes his company can put phage therapy back at the forefront.

Already Felix has tested its solution on an initial group of 10 people to demonstrate its approach.

\"\"

Felix researcher helping cystic fibrosis patient Ella Balasa through phage therapy

“We can develop therapies in less time and for less money than traditional antibiotics because we are targeting orphan indications and we already know our therapy can work in humans,” McBride told TechCrunch . “We argue that our approach, which re-sensitizes bacteria to traditional antibiotics could be a first line therapy.”

Felix plans to deploy its treatment in those suffering from cystic fibrosis first as there is no cure for this disease, which tends to require a near constant stream of antibiotics to combat lung infections.

The next step will be to conduct a small clinical trial involving 30 people, then, as the scientific research and development model tends to go, a larger human trial before seeking FDA approval. But McBride hopes his viral solution will prove itself out in time to help the coming onslaught of antibiotic resistance.

“We know the antibiotic resistant challenge is large now and is only going to get worse,” McBride said. “We have an elegant technological solution to this challenge and we know our treatment can work. We want to contribute to a future in which these infections do not kill more than 10 million people a year, a future we can get excited about.”

You Might Also Like

Enterprise Technology in 2026: Examples, Companies, Solutions & Trends

Social Media Branding Strategies for Startups: Build Trust and Grow Your Brand

DJI Osmo Pocket 3 Review 2026: Features, Pros, Cons and Is It Worth Buying?

How to Choose a Good Mobile Phone: 5 Tips for Buyers

Previous Article Rallyhood exposed a decade of users private data Rallyhood exposed a decade of users private data
Next Article Enable raises $13M to help distributors, manufacturers and retailers manage rebates Enable raises $13M to help distributors, manufacturers and retailers manage rebates

Latest News

Enterprise Technology in 2026: Examples, Companies, Solutions & Trends
Enterprise Nov 19, 2026
Social Media Branding Strategies for Startups: Build Trust and Grow Your Brand
Social Nov 13, 2026
DJI Osmo Pocket 3 Review 2026: Features, Pros, Cons and Is It Worth Buying?
Gadgets Nov 12, 2026
How to Choose a Good Mobile Phone: 5 Tips for Buyers
Mobile Nov 10, 2026
How to Raise Seed Funding for a Startup: A Complete Guide
Startups Nov 04, 2026
Startup Valuation Methods: How to Calculate Your Startup's Worth
Fundings and exits Nov 02, 2026
8GB vs 12GB RAM for Smartphone Performance: Which Is Better in 2026?
Mobile Oct 30, 2026
How to Store Solar Energy at Home: Batteries, Costs and Storage Options
Greentech Oct 27, 2026
Enterprise FinOps Tools for Cloud Spending: Top Platforms and Free Options
Enterprise Oct 22, 2026
Best Free Social Media Content Planning Tools: A Simple Guide
Social Oct 19, 2026
about us

  • Startups
  • Social
  • Enterprise
  • Gadgets
  • Greentech
  • Mobile
  • Fundings and exits
Latest Foldable Gadgets in 2026: Top Devices to Know
Latest Foldable Gadgets in 2026: Top Devices to Know
Gadgets Aug 18, 2026
Generative AI for Enterprise: Use Cases, ROI and Growth
Generative AI for Enterprise: Use Cases, ROI and Growth
Enterprise Aug 17, 2026

© Copyright 2026 thetechbrunch.com All Rights Reserved.

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms And Conditions